285 related articles for article (PubMed ID: 2906003)
21. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
22. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats.
Arnt J; Bøgesø KP; Hyttel J; Meier E
Pharmacol Toxicol; 1988 Mar; 62(3):121-30. PubMed ID: 3259694
[TBL] [Abstract][Full Text] [Related]
23. Dopamine D1 and D2 receptor agonists induce opposite changes in the firing rate of ventral pallidal neurons.
Maslowski RJ; Napier TC
Eur J Pharmacol; 1991 Jul; 200(1):103-12. PubMed ID: 1685119
[TBL] [Abstract][Full Text] [Related]
24. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
Breese GR; Napier TC; Mueller RA
J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
[TBL] [Abstract][Full Text] [Related]
25. Behavioural synergism between the dopamine agonists SKF 38393 and LY 171555 in dopamine-depleted mice: antagonism by sulpiride reveals only stimulant postsynaptic D-2 receptors.
Starr MS; Starr BS
Pharmacol Biochem Behav; 1989 May; 33(1):41-4. PubMed ID: 2571171
[TBL] [Abstract][Full Text] [Related]
26. Involvement of dopaminergic receptor subtypes in straub tail behaviour in mice.
Zarrindast MR; Bayat A; Shafaghi B
Gen Pharmacol; 1993 Jan; 24(1):127-30. PubMed ID: 8097737
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
Imperato A; Tanda G; Frau R; Di Chiara G
J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
[TBL] [Abstract][Full Text] [Related]
28. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets.
Löschmann PA; Smith LA; Lange KW; Jaehnig P; Jenner P; Marsden CD
Psychopharmacology (Berl); 1991; 105(3):303-9. PubMed ID: 1686813
[TBL] [Abstract][Full Text] [Related]
29. Neurophysiological evidence that D-1 dopamine receptor blockade attenuates postsynaptic but not autoreceptor-mediated effects of dopamine agonists.
Carlson JH; Bergstrom DA; Walters JR
Eur J Pharmacol; 1986 Apr; 123(2):237-51. PubMed ID: 2940101
[TBL] [Abstract][Full Text] [Related]
30. Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.
Ross SB; Jackson DM; Wallis EM; Edwards SR
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):512-8. PubMed ID: 3261844
[TBL] [Abstract][Full Text] [Related]
31. D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors.
Koller WC; Herbster G
Clin Neuropharmacol; 1988 Jun; 11(3):221-31. PubMed ID: 3261198
[TBL] [Abstract][Full Text] [Related]
32. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
Zarkovsky AM; Cereska KS
Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
[TBL] [Abstract][Full Text] [Related]
33. Electrophysiological effects of dopamine receptor stimulation in the hippocampus of Acomys cahirinus.
Bijak M; Danek L; Smiałowski A
Pol J Pharmacol Pharm; 1988; 40(5):535-41. PubMed ID: 2908137
[TBL] [Abstract][Full Text] [Related]
34. Contribution of the amygdala and nucleus accumbens to ventral pallidal responses to dopamine agonists.
Napier TC
Synapse; 1992 Feb; 10(2):110-9. PubMed ID: 1350111
[TBL] [Abstract][Full Text] [Related]
35. Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice.
Rubinstein M; Gershanik O; Stefano FJ
Eur J Pharmacol; 1988 Apr; 148(3):419-26. PubMed ID: 2968273
[TBL] [Abstract][Full Text] [Related]
36. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
37. SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons.
Breese GR; Mueller RA
Eur J Pharmacol; 1985 Jul; 113(1):109-14. PubMed ID: 2864260
[TBL] [Abstract][Full Text] [Related]
38. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
Subramaniam S; Lucki I; McGonigle P
Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
[TBL] [Abstract][Full Text] [Related]
39. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
40. Pressure reversed extracellular striatal dopamine decrease produced by D1 receptor agonist SKF 38393, and D2 receptor agonist LY 171555, but failed to change the effect of the activation of both D1 and D2 receptors.
Abraini JH; Fechtali T; Rostain JC
Neuroscience; 1992 Sep; 50(2):395-402. PubMed ID: 1359460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
